203 related articles for article (PubMed ID: 14555644)
1. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.
Lin HK; Hu YC; Yang L; Altuwaijri S; Chen YT; Kang HY; Chang C
J Biol Chem; 2003 Dec; 278(51):50902-7. PubMed ID: 14555644
[TBL] [Abstract][Full Text] [Related]
2. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
3. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
5. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
Yang L; Xie S; Jamaluddin MS; Altuwaijri S; Ni J; Kim E; Chen YT; Hu YC; Wang L; Chuang KH; Wu CT; Chang C
J Biol Chem; 2005 Sep; 280(39):33558-65. PubMed ID: 16061480
[TBL] [Abstract][Full Text] [Related]
6. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
Sharma M; Chuang WW; Sun Z
J Biol Chem; 2002 Aug; 277(34):30935-41. PubMed ID: 12063252
[TBL] [Abstract][Full Text] [Related]
8. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.
Lee SO; Lou W; Nadiminty N; Lin X; Gao AC
Prostate; 2005 Jul; 64(2):160-7. PubMed ID: 15678501
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.
Manin M; Baron S; Goossens K; Beaudoin C; Jean C; Veyssiere G; Verhoeven G; Morel L
Biochem J; 2002 Sep; 366(Pt 3):729-36. PubMed ID: 11971763
[TBL] [Abstract][Full Text] [Related]
10. Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways.
Górowska-Wójtowicz E; Hejmej A; Kamińska A; Pardyak L; Kotula-Balak M; Dulińska-Litewka J; Laidler P; Bilińska B
Toxicol In Vitro; 2017 Apr; 40():324-335. PubMed ID: 28163245
[TBL] [Abstract][Full Text] [Related]
11. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
Kim SM; Park JH; Kim KD; Nam D; Shim BS; Kim SH; Ahn KS; Choi SH; Ahn KS
Phytother Res; 2014 Mar; 28(3):423-31. PubMed ID: 23686889
[TBL] [Abstract][Full Text] [Related]
12. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
[TBL] [Abstract][Full Text] [Related]
13. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
14. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
[TBL] [Abstract][Full Text] [Related]
15. APPL suppresses androgen receptor transactivation via potentiating Akt activity.
Yang L; Lin HK; Altuwaijri S; Xie S; Wang L; Chang C
J Biol Chem; 2003 May; 278(19):16820-7. PubMed ID: 12621049
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells.
Yang L; Wang L; Lin HK; Kan PY; Xie S; Tsai MY; Wang PH; Chen YT; Chang C
Biochem Biophys Res Commun; 2003 Jun; 305(3):462-9. PubMed ID: 12763015
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
18. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Oncogene; 2008 Jun; 27(28):3986-98. PubMed ID: 18332867
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract][Full Text] [Related]
20. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells.
Lu S; Ren C; Liu Y; Epner DE
Int J Oncol; 2006 Jan; 28(1):245-51. PubMed ID: 16328002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]